Publications by authors named "S Lanes"
Article Synopsis
- The CAMP study is an ongoing research project aiming to assess the mid- and long-term effects of myocarditis and pericarditis following the Pfizer-BioNTech COVID-19 vaccine in patients under 21.
- It involves a cohort of at least 200 vaccinated patients and a comparison group of 100 patients with COVID-19 related myocarditis, collecting data over a 5-year span to track health outcomes and complications.
- As of October 16, 2024, the study has enrolled 273 participants, focusing on heart function, complications, and overall quality of life post-illness.
Article Synopsis
- Galcanezumab is a medicine used to help prevent migraines in adults, especially women who might get pregnant, but we don't know much about its safety during pregnancy yet.
- There's a study tracking pregnancies where women took galcanezumab, using health insurance data from September 2018 to June 2026, and they need 430 such cases to learn more about any potential risks.
- So far, they've found 207 pregnancies linked to the medicine but need many more to complete the study, which is an obstacle in getting safer pregnancy information out to doctors and patients.
Article Synopsis
- Real-world evidence (RWE) is being increasingly utilized in medical regulatory decisions, but there are ongoing concerns about its reproducibility and validity due to diversity across real-world data sources (RWDS).
- This study aimed to identify practices and tools for collecting and reporting diversity in RWDS, as well as to explore how leveraging this diversity can enhance the quality of evidence in pharmacoepidemiology.
- The analysis of 91 selected documents revealed 12 key topics about RWDS diversity, highlighting opportunities and challenges, ultimately providing a foundation for better guidance on data reporting to improve the replicability and validity of RWE.
Background: Large health insurance claims databases can be used to estimate rates of rare safety outcomes. We measured incidence rates of rare outcomes that could be used to contextualize adverse events among people receiving pneumococcal vaccines in clinical trials or clinical practice. However, algorithms used to identify outcomes in administrative databases are subject to error.
View Article and Find Full Text PDFObjective: To assess risk of anaphylaxis among patients with type 2 diabetes mellitus who are initiating therapy with a glucagon-like peptide 1 receptor agonist (GLP-1 RA), with a focus on those starting lixisenatide therapy.
Research Design And Methods: A cohort study was conducted in three large, U.S.